Montreal / August 23, 2026 A historic moment for FBC Montréal 2026! For the first time in FBC's history, there was a tie for first place between two incredible founders: Nadia Ladak, founder of Marlow, and Valérie Léveillé, founder of NexPlasmaGen. The cohort of FBC Montreal finalists...
Montreal / May 4, 2026 – NexPlasmaGen will present its business plan at the TiEQuest Summit 2026 on May 26 from 8:30 AM to 12:30 PM EDT before investors at the Schwartz Reisman Innovation Campus at the University of Toronto. TieQuest 2026 (TiEQuest 2026 | TiE...
March 08, 2025, The CHUM site is activated to begin patient recruitment for safety clinical trials with NexPlasmaGen medical technology Montreal / March 08, 2025 - The Centre hospitalier de l'Université de Montréal (CHUM) site has been activated to begin recruiting patients for safety trials with NexPlasmaGen's...
Montreal / September 19, 2024 - NexPlasmaGen wins the Corporate Livewire magazine's Innovation and Excellence Award - Cancer Treatment Technology Company of 2024 The Corporate LiveWire Innovation & Excellence Awards celebrate the success and achievements of leading professionals and companies who have stood out for being...
Montreal / August 8, 2024 - NexPlasmaGen is pleased to announce that Mr. David Uffer and Mr. Edward J. Dougherty have joined NexPlasmaGen! David Uffer, M.A, MBA joins NexPlasmaGen's Board of Directors. David is a 30+ yr seasoned executive having a career dedicated to the Medtech...
Montreal / April 19, 2024 - NexPlasmaGen is honored to announce that it has won GHP magazine's Best MedTech Oncology Business - Canada 2024 award. "GHP Magazine's Biotechnology Awards 2024” are designed to recognize and honor the most valuable contributors to the biotechnology industry, as well...
Montreal / April 05, 2024 - NexPlasmaGen is pleased to announce that on February 6, 2024, the 2nd U.S. patent (US 11895763B2) was granted for its medical technology developed for the treatment of breast cancer. NexPlasmaGen has exclusive rights to this patent under license from...
Montreal / April 21, 2023 - NexPlasmaGen announces that it has received $511,186 in funding from the ministère de l'économie, de l'innovation et de l’Énergie (MEIE) du Québec and the Québec Breast Cancer Foundation (QBCF) to conduct clinical safety trials with its Convertible Plasma Jet...
NEXPLASMAGEN TO PRESENT AT THE 2023 OBIO INVESTMENT SUMMIT Canada’s Premier Health Science Investment Event! Montreal/February 2, 2022 – NexPlasmaGen is proud to announce that it is presenting at 2023 OBIO Investment Summit. The OBIO Investment Summit will be hosted at the World Trade Centre Toronto on February...
Montreal / July 4, 2022 NexPlasmaGen is a finalist for the ADRIQ Innovation Award 2022 in the category Innovation from Public Research. The Innovation Awards Gala has become a must-attend event in the Quebec ecosystem. The 32nd ADRIQ Innovation Awards Gala will take place on Thursday, November...